Innovhem
Innovhem is a biotech research company focused on improving the health of sickle cell patients by developing innovative biomarkers and clinical algorithms. Their solutions aim to assess treatment efficacy, guide physicians in personalizing treatments, and predict health events like painful crises. The company offers services to pharma and biotech companies for validating clinical claims. Innovhem's core innovations include single-cell quantification of fetal hemoglobin and intravascular hemolysis biomarkers, as well as predictive clinical scores leveraging machine learning. They position themselves to change the paradigm of sickle cell medical care by addressing a high unmet medical need due to a lack of treatments and poor utility of standard-of-care. Innovhem's strategy involves close collaboration with academic institutions and industry partners, supported by various French and European innovation programs. The company has secured patents for its single-cell HbF quantification method. Their team comprises co-founders with expertise in CEO and CSO roles, supported by project managers and quality managers.
Innovhem
Innovhem is a biotech research company focused on improving the health of sickle cell patients by developing innovative biomarkers and clinical algorithms. Their solutions aim to assess treatment efficacy, guide physicians in personalizing treatments, and predict health events like painful crises. The company offers services to pharma and biotech companies for validating clinical claims. Innovhem's core innovations include single-cell quantification of fetal hemoglobin and intravascular hemolysis biomarkers, as well as predictive clinical scores leveraging machine learning. They position themselves to change the paradigm of sickle cell medical care by addressing a high unmet medical need due to a lack of treatments and poor utility of standard-of-care. Innovhem's strategy involves close collaboration with academic institutions and industry partners, supported by various French and European innovation programs. The company has secured patents for its single-cell HbF quantification method. Their team comprises co-founders with expertise in CEO and CSO roles, supported by project managers and quality managers.